Immunogenicity and safety of heterologous prime boost COVID-19 vaccines in Thailand
Phase 2
Recruiting
- Conditions
- The immune response after heterologous COVID-19 vaccine administration in healthy volunteers.COVID-19 vaccine, heterologous prime-boost, ChAdOx1, coronavac, Sinovac.
- Registration Number
- TCTR20210714003
- Lead Sponsor
- Chulabhorn Royal Academy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 264
Inclusion Criteria
1. 18 years old or more 2. Negative urine pregnancy test (in case of potential of pregnancy) 3. No history of a severe allergic reaction to the prior vaccine. 4. No fever nor history of fever within 14 days. 5. No symptoms of respiratory tract infection within 14 days. 6. sign informed consent to the study.
Exclusion Criteria
1. prior COVID-19 vaccination. 2. pregnancy. 3. lactation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Humoral immunity 4 weeks after boosted dose 4 weeks after the boosted dose of the vaccine Double antigen technique for detection of Antibody level of total antibody of spike protein of SARS-CoV-2
- Secondary Outcome Measures
Name Time Method proportion of seroconversion after vaccination 4 weeks after the boosted dose of the vaccine Double antigen technique for detection of Antibody level of total antibody of spike protein of SARS-CoV-2,Safety profile after vaccination in each intervention arms 4 week after each dose of vaccine Solicited adverse events